Tonix Pharmaceuticals to Present at Two Investor Conferences in May 2026

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026: the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. The presentations will provide updates on the company’s commercial and clinical-stage portfolio, including its recently approved fibromyalgia treatment, TONMYA.

Tonix is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Beyond fibromyalgia, Tonix is evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, aiming to expand its therapeutic potential.

The company’s CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In immunology, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. These programs address significant unmet medical needs and represent potential growth drivers for the company.

Participation in these conferences underscores Tonix’s commitment to engaging with the investment community and highlighting its progress. The RBC Capital Markets Global Healthcare Conference is a premier event for healthcare investors, while A.G.P.’s virtual conference provides broad access to institutional and retail investors. Interested parties can find more details in the full press release at https://ibn.fm/ZZpG2.

Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. For the latest news and updates regarding TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.